Apellis Pharmaceuticals, Inc.APLSNASDAQ
Loading
Year-over-year research & development expense growth
| Period | Value |
|---|---|
| Q4 2025 | 8.87% |
| Q3 2025 | 1.75% |
| Q2 2025 | -22.45% |
| Q1 2025 | 13.18% |
| Q4 2024 | -13.79% |
| Q3 2024 | 13.63% |
| Q2 2024 | -7.97% |
| Q1 2024 | 22.26% |
| Q4 2023 | -12.77% |
| Q3 2023 | -16.97% |
| Q2 2023 | -13.06% |
| Q1 2023 | 10.67% |
| Q4 2022 | 4.43% |
| Q3 2022 | -6.35% |
| Q2 2022 | 11.78% |
| Q1 2022 | -15.93% |
| Q4 2021 | 23.31% |
| Q3 2021 | -39.89% |
| Q2 2021 | 73.72% |
| Q1 2021 | 11.44% |
| Q4 2020 | -19.12% |
| Q3 2020 | 7.02% |
| Q2 2020 | 25.71% |
| Q1 2020 | -11.71% |
| Q4 2019 | 52.91% |
| Q3 2019 | 1.22% |
| Q2 2019 | 25.24% |
| Q1 2019 | 31.40% |
| Q4 2018 | 4.29% |
| Q3 2018 | 7.27% |
| Q2 2018 | 58.24% |
| Q1 2018 | 32.51% |
| Q4 2017 | 37.98% |
| Q3 2017 | -8.67% |
| Q2 2017 | 44.13% |
| Q1 2017 | 29.31% |
| Q4 2016 | -10.30% |
| Q3 2016 | 11.80% |
| Q2 2016 | 0.00% |
| Q1 2016 | 41.96% |